Shenlin Huang

Shenlin Huang

Auto-generated profile, based on publicly available information

Shenlin Huang

BioTheryx, Inc., San Diego, California

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Mutations within the oncogene KRAS drive an estimated 25% of all cancers. Only allele-specific KRAS G12C inhibitors are currently available and are associated with the emergence of acquired resistance, partly due to upstream pathway reactivation. Given its upstream role in the activation of KRAS, son of sevenless homolog 1 (SOS1), has emerged as an attractive therapeutic target. Agents that target SOS1 for degradation could represent a potential pan-KRAS modality that may be capable of circumventing certain acquired resistance mechanisms. Here, we report the development of two SOS1 cereblon-based bifunctional degraders, BTX-6654 and BTX-7312, cereblon-based bifunctional SOS1 degraders. Both compounds exhibited potent target-dependent and -specific SOS1 degradation. BTX-6654 and BTX-7312 reduced downstream signaling markers, pERK and pS6, and displayed antiproliferative activity in cells harboring various KRAS mutations. In two KRAS G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. Altogether, BTX-6654 provided preclinical proof of concept for single-agent and combination use of bifunctional SOS1 degraders in KRAS-driven cancers.

6 March 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SHShenlin Huang
Shenlin Huang
ZLZuosheng Liu
Zuosheng Liu
STShin-Shay Tian
Shin-Shay Tian
MSMark Sandberg
Mark Sandberg
TSTracy A. Spalding
Tracy A. Spalding
YHYun He
Yun He

2 April 2024
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S4 displays the IC50 values for BTX-6654 and BTX-7312 from all 3D proliferation assays examined in this study

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S5 shows the IC50 values for SOS1 inhibitors in 3D proliferation assays for KRAS G12D cell lines

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S3 lists the EC50 and IC50 values for ternary complex formation and SOS1 binding for compounds used in this study

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Figure S1 displays the effects of SOS1 degraders on SOS1-complex interactors and neosusbstrates